Zions Bancorporation N.A. Purchases 1,396 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Zions Bancorporation N.A. increased its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 19.6% during the 4th quarter, Holdings Channel reports. The firm owned 8,514 shares of the company’s stock after acquiring an additional 1,396 shares during the period. Zions Bancorporation N.A.’s holdings in Medpace were worth $2,829,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of MEDP. EntryPoint Capital LLC raised its holdings in Medpace by 67.4% during the fourth quarter. EntryPoint Capital LLC now owns 1,503 shares of the company’s stock valued at $499,000 after acquiring an additional 605 shares during the period. Congress Wealth Management LLC DE grew its position in shares of Medpace by 1.7% during the fourth quarter. Congress Wealth Management LLC DE now owns 12,288 shares of the company’s stock worth $4,082,000 after purchasing an additional 209 shares in the last quarter. Summit Creek Advisors LLC raised its stake in Medpace by 0.3% during the 4th quarter. Summit Creek Advisors LLC now owns 47,808 shares of the company’s stock valued at $15,883,000 after purchasing an additional 146 shares during the period. Vanguard Group Inc. lifted its holdings in Medpace by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 2,570,770 shares of the company’s stock worth $854,087,000 after purchasing an additional 25,704 shares in the last quarter. Finally, LPL Financial LLC boosted its stake in Medpace by 5.3% in the 4th quarter. LPL Financial LLC now owns 17,960 shares of the company’s stock worth $6,010,000 after purchasing an additional 909 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on MEDP. Leerink Partners started coverage on Medpace in a report on Monday. They issued a “market perform” rating and a $330.00 target price on the stock. Leerink Partnrs raised Medpace to a “hold” rating in a report on Monday. Finally, Robert W. Baird raised their target price on shares of Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Nine equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $376.30.

Medpace Trading Down 1.8 %

Shares of NASDAQ:MEDP opened at $324.51 on Wednesday. The company has a market capitalization of $9.89 billion, a price-to-earnings ratio of 25.69, a PEG ratio of 3.81 and a beta of 1.47. Medpace Holdings, Inc. has a 12 month low of $302.01 and a 12 month high of $459.77. The firm’s 50-day moving average is $337.16 and its 200 day moving average is $339.57.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. As a group, equities analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.